^
    Back
    Association details:
    Biomarker:NTRK3 fusion
    Cancer:Pancreatic Adenocarcinoma
    Drug:Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pancreatic Adenocarcinoma: Useful in Certain Circumstances...Larotrectinib (if NTRK gene fusion positive)...
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Sarcoma)
    New
    Title:

    New sarcoma drug approved for use in England

    Excerpt:
    We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    JNCCN 360
    Title:

    Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature

    Published date:
    01/06/2021
    Excerpt:
    Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma...The study describes the first reported patient with NTRK gene fusion in PACC. Ongoing partial response to larotrectinib was attained…
    DOI:
    10.6004/jnccn.2020.7641